NCT00176774已完成2 期
A Pilot Trial of Irinotecan, 5-Fluorouracil, and Leucovorin Combined With the Anti-Angiogenesis Agent Tetrathiomolybdate in Metastatic Colorectal Carcinoma (UMCC 0075)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- OBJECTIVES
研究概览
简要总结
This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM) combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV). This study will evaluate the safety and tolerability of the combination of these drugs when they are used in the treatment of metastatic colorectal cancer.
This is a pilot clinical trial which will be studying the reactions of the patient's body and tumor to the experimental treatment described above. The purpose of this study is to find out what kind of side effects this experimental treatment causes and see how often these side effects occur.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically proven adenocarcinoma primary to the colon or rectum and clinical or pathologic evidence of distant metastasis.
- •Patients may have received adjuvant chemotherapy and/or one regimen of chemotherapy for metastatic disease. Patients must not have been previously treated with the combination of irinotecan/5-FU/LV.
- •Patients must be past their 18th birthday at the time of enrollment.
- •Patients must have a performance status of 0-2 at the time of registration.
- •Patients must have a life expectancy of > 3 months.
- •If patients have undergone recent surgery, they must have fully recovered from the effects of that surgery prior to enrollment.
- •Patients must have a pretreatment leukocyte count > 3,000/l, absolute neutrophil count >1500/l, hemoglobin >8 mg/dl, and platelet count of > 150,000/l within 2 weeks of enrollment.
- •Patients must have adequate renal function, as documented by a serum creatinine < 2.0 mg/dl, and have adequate hepatic function, as documented by a serum bilirubin < 1.1 mg/dl within 2 weeks of enrollment.
排除标准
- •Patients must not have active infection.
- •Patients must have no serious medical or psychiatric illness, other than that treated by this study, which would limit the ability of the patient to receive protocol therapy or give informed consent.
- •Patients must not have a history of active malignancy, other than that treated by this study, within the 12 months preceding enrollment.
- •Pregnant or lactating women may not participate. Women of reproductive age must undergo a serum pregnancy test within 14 days of enrollment. Men and women of reproductive potential must use an effective contraceptive method during the study.
- •There must be no plans for the patient to receive concomitant antineoplastic therapy while on this protocol.
- •All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
结局指标
主要结局
OBJECTIVES
时间窗: 12 months
To determine the tolerability and toxicity of tetrathiomolybdate (TM) in combination with irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer.
时间窗: 12 months
Toxicity
时间窗: 12 months
次要结局
- To evaluate the progression free survival in patients with metastatic colorectal cancer when treated with this regimen.(24 months)
- To determine the tolerability and toxicity of tetrathiomolybdate (TM) in combination with irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer.(12 months)
- To determine the success rate of TM leading to target levels of copper depletion in patients treated concurrently with chemotherapy(12 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI TumoursUpper Gastrointestinal TumoursNCT00220064Royal Marsden NHS Foundation Trust65
终止
1 期
A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT00819754Ottawa Hospital Research Institute23
进行中（未招募）
2 期
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing SarcomaNewly Diagnosed Ewing SarcomaNCT01864109Memorial Sloan Kettering Cancer Center83
Unknown
3 期
FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer PatientsColorectal CarcinomaNCT02935764Fudan University164
已完成
2 期
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal CancerColorectal CancerNCT01205711Cardiff University111